KOL event highlights vafidemstat potential in BPD

At Oryzon Genomics’ key opinion leader (KOL) event, vafidemstat’s path through Phase III in borderline personality disorder (BPD) was laid out. The significant unmet need was highlighted, as there are currently no FDA-approved drugs specifically indicated for BPD, despite a global prevalence of 1–2%, and clinicians are limited to prescribing medications (such as antipsychotics and/or mood stabilisers) off-label, often with limited durable effectiveness. Given vafidemstat’s encouraging track record in the clinic targeting agitation and aggression (A/A) in BPD, alongside its novel epigenetic mechanism of action, the KOLs spoke about their willingness to use vafidemstat with their patients, especially since this symptom domain is one of the...